Intensive cholesterol-lowering therapy improves large artery elasticity in acute myocardial infarction patients

Xinwei, Jia; Wang, Meng; Fu, Xianghua; Gu, Xing; Fan, Wei; Zhang, Jing; Li, Xue

doi:10.1007/s00380-008-1132-z

Cited by 14 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Measuring baPWV, a parameter closely correlated with aortic PWV and carotid-femoral PWV, which are well-established vascular tests for the evaluation of atherosclerosis and cardiovascular risks 10,11) , is easy to perform. In previous studies, cardiovascular risk reduction has been shown to be related to the improvement of baPWV after modification of atherosclerotic risk burden, including BP lowering, LDL lowering, and glucose lowering [19][20][21] . FMD, a marker of endothelium-dependent dilation of the brachial artery, reflects systemic endothelial function, as well as atherosclerotic risk burden at the time of FMD measurement.…”

Section: Discussionmentioning

confidence: 96%

Improvement in Brachial Endothelial Vasomotor Function and Brachial-Ankle Pulse Wave Velocity Reduces the Residual Risk for Cardiovascular Events after Optimal Medical Treatment in Patients with Coronary Artery Disease

Nakamura

Uematsu

Horikoshi

et al. 2021

JAT

View full text Add to dashboard Cite

To examine whether improvement in flow-mediated endothelium-dependent dilatation (FMD) of the brachial artery and brachial-ankle pulse wave velocity (baPWV) has an additive effect on achieving optimal goals of traditional risk factors to reduce cardiovascular risk in patients with coronary artery disease (CAD). Methods: We assessed 323 patients with CAD and impaired vascular function, defined as an impaired FMD of the brachial artery (5.5%) and increased baPWV (1,440 cm/sec). After FMD and baPWV measurements at 24 weeks of optimal medical treatment (OMT), the study patients were followed up for 60 months or until a composite of cardiac death, nonfatal myocardial infarction (MI), unstable angina, or ischemic stroke occurs. Results: During the median follow-up period of 35 months, cardiovascular events occurred in 72 patients. Multivariate Cox hazards analysis showed that patients with an improvement in FMD and baPWV had the lowest probability of future cardiovascular events. In addition, the improvement in FMD and baPWV had a significant incremental effect on the predictive value of the achievement of optimal goals for blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), and hemoglobin A1c (HbA1c) using net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Conclusions: The improvement in FMD and baPWV had additive effects on risk reduction of the achievement of the optimal goals of traditional risk factors in patients with CAD. Thus, serial measurements of FMD and baPWV may be useful for identifying CAD patients at residual risk for adverse cardiovascular events following OMT. residual risk of secondary cardiovascular events, even after achieving the optimal therapeutic goals in patients with CAD, is important. Recent studies suggest that vascular dysfunction is not merely a local vascular occurrence; instead, it exists at multiple sites in the systemic vascular bed 4, 5). Vascular dysfunction, such as endothelial dysfunction and increased arterial stiffness, influences the development of atherosclerosis and leads to cardiovascular events 6-9). Relevant vascular function Copyright©2020 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.

show abstract

Section: Discussionmentioning

confidence: 96%

Improvement in Brachial Endothelial Vasomotor Function and Brachial-Ankle Pulse Wave Velocity Reduces the Residual Risk for Cardiovascular Events after Optimal Medical Treatment in Patients with Coronary Artery Disease

Nakamura

Uematsu

Horikoshi

et al. 2021

JAT

View full text Add to dashboard Cite

show abstract

“…To date, many clinical trials have reported serum LDL-C along with HDL-C, the LDL-C/HDL-C ratio, hs-CRP, and other parameters as markers of inhibition of progression and/or regression of coronary plaques [5,6,[11][12][13][14][15][16][17]. The characteristics of the patients to be treated and the types of statins to be used will determine which of the factors might be a better predictor of coronary plaque regression.…”

Section: Discussionmentioning

confidence: 99%

Development of a model for prediction of coronary atherosclerotic regression: evaluation of high-density lipoprotein cholesterol level and peripheral blood monocyte count

et al. 2011

View full text Add to dashboard Cite

Monocytes and high-density lipoprotein cholesterol (HDL-C) play important roles in the process of coronary atherosclerosis. We hypothesized that a reasonable predictive model of coronary plaque regression might be constructed using the change in the peripheral monocyte count and the serum HDL-C level. The plaque volume, as assessed by volumetric intravascular ultrasound, was measured at the baseline and after 6 months of pravastatin therapy in 114 patients with coronary artery disease. After 6 months of pravastatin therapy, a significant decrease of the plaque volume by 9.9% (p < 0.0001, vs. baseline) was observed; furthermore, a corresponding increase of the serum HDL-C level and decrease of the peripheral blood monocyte count were also seen (12.5%, p < 0.01 and -7.3%, p < 0.0001). In a multivariate regression analysis using the serum lipids and traditional risk factors as the covariates, the increase in the serum HDL-C (β -0.56, p < 0.0001) and the decrease in monocyte count (β 0.23, p = 0.03) were identified as independent predictors of the plaque regression. A model for the prediction of plaque regression according to whether the achieved the change in (Δ) monocyte count and ΔHDL-C were above or below the median values was prepared. Among the four groups, the group with ΔHDL-C ≥8.8% and Δmonocyte count ≤-8.6% showed the largest plaque regression (-20.4%), and the group with ΔHDL-C <8.8% and Δmonocyte count >-8.6% showed the increase of the plaque volume (2.6%). In view of the inflammatory nature of atherosclerosis, the model constructed using the two predictors may be a useful model for the prediction of plaque regression.

show abstract

“…The transcriptional regulation of the human PTGIS gene is poorly understood. The core PTGIS promoter contains several presumed cis-acting elements for different transcription factors like Sp1, NFB and AP-2, which have been shown to be linked to induction of other genes after treatment with statins [124,125]. The PTGIS promoter activity has been shown to be regulated by epigenetic mechanisms in human cancer cells [122,126] but the genetic regulation in normal cells is not well studied.…”

Section: 431mentioning

confidence: 99%

Statins inhibit expression of Thioredoxin reductase 1 in rat and human liver and reduce tumour development

Skogastierna

Johansson

Parini

et al. 2012

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Intensive cholesterol-lowering therapy improves large artery elasticity in acute myocardial infarction patients

Cited by 14 publications

References 27 publications

Improvement in Brachial Endothelial Vasomotor Function and Brachial-Ankle Pulse Wave Velocity Reduces the Residual Risk for Cardiovascular Events after Optimal Medical Treatment in Patients with Coronary Artery Disease

Improvement in Brachial Endothelial Vasomotor Function and Brachial-Ankle Pulse Wave Velocity Reduces the Residual Risk for Cardiovascular Events after Optimal Medical Treatment in Patients with Coronary Artery Disease

Development of a model for prediction of coronary atherosclerotic regression: evaluation of high-density lipoprotein cholesterol level and peripheral blood monocyte count

Statins inhibit expression of Thioredoxin reductase 1 in rat and human liver and reduce tumour development

Contact Info

Product

Resources

About